From Yahoo Finance: 2025-06-12 12:49:00

BioNTech acquires CureVac for $1.25bn to focus on mRNA cancer treatments. Each CureVac share will be exchanged for $5.46 in BioNTech ADS. The deal aims to combine expertise in mRNA medicine. BioNTech’s shares rose 0.17% after the announcement, with a market cap of $25.3bn.

BioNTech strengthens its position in mRNA-based cancer immunotherapies with the acquisition. The company aims to advance innovative cancer treatments and set new standards of care. CureVac shifted focus to oncology in 2024 after selling influenza and Covid-19 vaccine development to GSK for nearly €1.5bn.

This is BioNTech’s second major oncology deal this month, following a licensing agreement with MSD for a bispecific cancer drug with a potential value of $11bn. BioNTech’s CEO envisions the acquisition as a step towards the future of cancer medicine, leveraging technologies to develop transformative treatments.

In November 2024, BioNTech also acquired oncology biotech Biotheus for $800m, further enhancing its cancer platform. The company continues to expand its mRNA pipeline and solidify its position in the oncology market. The goal is to establish new standards of care for various types of cancer in the coming years.

Read more: BioNTech bolsters mRNA pipeline with $1.25bn CureVac acquisition